Dashboard
Portfolio compliance overview
Active Studies
12
+2 this quarter
Avg Readiness Score
78
+4 from last month
Critical Gaps Open
4
3 resolved this week
Certificates Issued
23
5 this month
Study Readiness
| Study | Sponsor | Score | Grade | Critical |
|---|---|---|---|---|
| Phase III BEACON-CML STUDY-001 | Gilead Sciences | 92 | A | None |
| Phase II NOVA-AML STUDY-002 | Bristol Myers Squibb | 78 | C | 2 |
| Phase I HORIZON-MDS STUDY-003 | Novartis | 65 | D | 3 |
| Phase III APEX-ALL STUDY-004 | Amgen | 88 | B | 1 |
| Phase II STELLAR-MM STUDY-005 | Johnson & Johnson | 45 | F | 7 |
Phase III BEACON-CML
STUDY-001
92A
Critical
0
Major
3
Minor
2
Top Gaps
CRITICALMonitoring visit frequency below threshold
MAJORMissing investigator qualification records
CRITICALIRB approval renewal overdue
Recent Certificates
| Certificate ID | Study | Issued | Status | Actions |
|---|---|---|---|---|
| CERT-2025-001 | BEACON-CML | 2025-03-15 | Valid | |
| CERT-2025-002 | APEX-ALL | 2025-03-10 | Valid | |
| CERT-2025-003 | NOVA-AML | 2025-02-28 | Expired |